Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Neuroendocrine Neoplasm Based on Multi-omics Integrated Analysis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04931446
Recruitment Status : Not yet recruiting
First Posted : June 18, 2021
Last Update Posted : June 18, 2021
Sponsor:
Information provided by (Responsible Party):
Xian-Jun Yu, Fudan University

Brief Summary:
This project intends to analyze the molecular biological characteristics of NEN based on multi-omics, develop an exclusive NEN multi-omics big data platform, and carry out molecular subtypes and potential targets prediction, so as to improve the therapeutic effect of neuroendocrine tumors.

Condition or disease Intervention/treatment
Neuroendocrine Neoplasm Procedure: Biopsy/surgical tissue and peripheral blood

Detailed Description:

In recent years, the innovation of high-throughput sequencing technology has greatly promoted the understanding of disease mechanisms at the molecular level. It is an indisputable fact that there are large differences in the prognosis of tumors with the same pathological type and stage clinically. A large number of studies have proved that the difference in prognosis is closely related to the heterogeneity of the tumor. In the past few years, individualized precision treatment can greatly improve the prognosis of patients. Studies have shown that subgroup classification of colorectal cancer based on somatic mutations and signal pathway activation in the TCGA database has greatly improved the accuracy of diagnosis and the effectiveness of treatment. Lehmann's team divided the samples into six types based on the gene expression profile of triple-negative breast cancer: immunomodulatory type, mesenchymal type, mesenchymal stem-like type, androgen receptor type, and two basal-like types. This typing method combines the role of normal matrix and immune cell transcription levels in the tumor microenvironment, and explores their clinical characteristics and treatment strategies according to different subtypes. However, no single omics is sufficient to elucidate the complex pathogenesis of tumors. Therefore, the integrated analysis of multiple omics is a development trend, which will help clarify the pathogenesis of tumors and discover potential drug treatment targets. The interactive analysis of phenotypic data and molecular omics data can not only help us analyze the correlation between biological phenotypes and molecular phenotypes, but also allow us to understand the microscopic molecular mechanism of macro-biological phenotypes. For example, imaging phenotypes based on CT and MRI can be used to explore important protein markers related to them, which provides experimental and theoretical basis for guiding future clinical drug targeted therapy and drug resistance mechanism research. What's more interesting is that the relationship between molecular classification of tumors based on molecular omics and the establishment of phenotypic recognition models such as imaging omics can also make phenotypics such as imaging omics become a guide for targeted tumor therapy. An important method. Therefore, for neuroendocrine tumors with a high degree of heterogeneity, it is very necessary to analyze them from the perspective of multiple omics. However, in the current public databases TCGA and GEO, the exclusive NEN genomics data is extremely scarce, and there are almost no data such as proteomics, epiomics, metabolomics, and imagingomics. Therefore, it is urgent to carry out exclusive NEN multi-omics big data analysis to comprehensively and in-depth study the genesis and development mechanism of neuroendocrine tumors.

This project intends to analyze the molecular biological characteristics of NEN based on multi-omics analysis, develop an exclusive NEN multi-omics big data platform, and carry out molecular subtypes. We hope that this study can find the molecular mechanism and potential intervention targets of NEN recurrence and metastasis, and provide clinicians with safe and effective treatment strategies, thereby improving the therapeutic effect of neuroendocrine tumors.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 200 participants
Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Research on Neuroendocrine Neoplasm in a Single Center Based on Multi-omics Integrated Analysis
Estimated Study Start Date : July 2021
Estimated Primary Completion Date : March 2022
Estimated Study Completion Date : December 2022

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Gastroenteropancreatic neuroendocrine neoplasms Procedure: Biopsy/surgical tissue and peripheral blood
Retrieve specimens stored in the tissue bank, the main types of samples are RNAlater specimens, liquid nitrogen frozen specimens and peripheral blood specimens




Primary Outcome Measures :
  1. NEN mechanism analysis based on Multi-omics [ Time Frame: One year ]
    Collect NEN tissue specimens and peripheral blood specimens for genomics, transcriptomics, proteomics, phosphorylation, metabolomics and other multiple omics sequencing analysis, so as to find the relationship between these molecular omics and phenotypes, explore NEN mechanism, including driver genes, activation of signal pathways, etc., and screen sensitive drugs based on potential targets. Use multi-omics data to establish NEN big data analysis platform, including sensitive target prediction, related gene prediction, survival analysis, and so on.


Secondary Outcome Measures :
  1. NEN immune microenvironment analysis [ Time Frame: One year ]
    The GSVA software and CIBORSORT method are used to predict the content and ratio of various immune cell subtypes based on NEN mRNA expression.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Collect gastrointestinal pancreatic neuroendocrine tumor samples stored in the tissue bank of Fudan University Affiliated Tumor Hospital from January 31, 2010 to March 31, 2021
Criteria

Inclusion Criteria:

  1. Received surgical treatment at Fudan University Affiliated Cancer Hospital from January 2010 to January 2021;
  2. Postoperative pathology proved to be neuroendocrine tumor;
  3. Has signed an informed consent form for tissue bank sample collection, agreeing to use the specimens and related clinical data for scientific research.

Exclusion Criteria:

  1. Merge other malignant tumors;
  2. The clinical data is missing.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04931446


Contacts
Layout table for location contacts
Contact: Xianjun Yu, MD, PhD +86-13801669875 yuxianjun@fudanpci.org

Locations
Layout table for location information
China, Shanghai
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University
Shanghai, Shanghai, China, 200032
Contact: XianJun Yu, M.D., Ph.D.    +86-21-6417-5590    yuxianjun@fudanpci.org   
Principal Investigator: Xianjun Yu, M.D., Ph.D.         
Sponsors and Collaborators
Xian-Jun Yu
Investigators
Layout table for investigator information
Principal Investigator: Xianjun Yu, MD, PhD Fudan University
Publications:

Layout table for additonal information
Responsible Party: Xian-Jun Yu, President of Shanghai Pancreatic Cancer Institute, Fudan University
ClinicalTrials.gov Identifier: NCT04931446    
Other Study ID Numbers: CSPAC-NEN-2
First Posted: June 18, 2021    Key Record Dates
Last Update Posted: June 18, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Xian-Jun Yu, Fudan University:
Neuroendocrine Neoplasm
Multi-omics Analysis
Molecular Subtypes
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue